AlphAIalphai — Financial news for AI agents
Zacks CommentaryNOV 73 min read$CHRS

Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates

Coherus Oncology (CHRS) delivered earnings and revenue surprises of -3.13% and -5.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Original reporting
Zacks Commentary · Zacks Equity Research
Published Nov 7, 2025, 1:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 7, 2025, 3:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates — source image
Source · www.zacks.com
Decision brief

The 30-second read

$CHRSBearishMed
01

Why it matters

The Q3 earnings report has led to a reassessment of the company's short-term prospects, with investors possibly reacting negatively.

02

Market read

The news is highly relevant for traders holding or considering positions in CHRS or related biotech stocks.

03

What to watch

Potential upcoming drug approvals or partnerships could offset current negatives; broader industry tailwinds may support the stock in the medium term.

Timing: Immediate, as earnings reports influence trading today and in the short term.

Background

Coherus Oncology operates in the biotech sector, focusing on oncology therapeutics. The company recently faced challenges with product development and market competition.

Company-level read

Ticker impact

$CHRSBearishMedium confidence
Context

The company's recent earnings report indicates a quarterly loss and revenue miss, which may influence short-term trading decisions.

Expected impact

Moderate decline expected in the next 1-2 weeks, approximately 3-5%.

Evidence & confidence

The earnings miss and negative surprise indicate short-term weakness, but the company's long-term prospects depend on upcoming catalysts and industry trends.

Market effects

Sector

The biotech and oncology sector may experience slight negative sentiment due to the earnings miss, affecting peer stocks.

Regional

Limited regional impact; primarily affects US-based biotech stocks.

Global

Low; the news is company-specific with minimal global market implications.

Counterpoint

What could challenge this read

The earnings miss may be a temporary setback; if the company announces positive catalysts soon, the stock could rebound.

Key entities

  • Company
    Coherus Oncology

    A biotech firm specializing in oncology treatments.

Read at source← All news

Related articles

AUG 13
$CHRSMedAI 8/10

Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript

Coherus Oncology (CHRS) reported Q2 2026 results on an earnings call. LOQTORZI net revenue was $13.6M, up 15% sequentially and 37% YoY. Full-year LOQTORZI guidance is $57M to $62M. Total net revenue from continuing ops was $14.3M. Cash and marketable securities were $105.3M at June 30, 2026.

fool.com6 min
AUG 7
$CHRSMed

Coherus Oncology Q2 Earnings Call Highlights

Coherus Oncology (NASDAQ:CHRS) reported Q2 updates on tagmokitug and LOQTORZI during an earnings call. It said preliminary head and neck response and biomarker findings are based on limited patients, with formal disclosure expected in October. LOQTORZI net sales were $13.6M, up 15% sequentially. Full-year 2026 LOQTORZI revenue guidance is $57M to $62M; 2026 operating expenses $170M to $175M.

yahoo.com6 min
AUG 5
$CHRSMed

Coherus Oncology, Inc. (CHRS): Results of Operations and Financial Condition

Coherus Oncology, Inc. (CHRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 chrs-20260805xex99d1.htm EX-99.1 Exhibit 99.1 ​ Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update ​ – LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – ​ – Clinical data continue to mature across programs with

SEC EDGAR 8-K6 min
AUG 18
$RKLBMedAI 8/10

Rocket Lab Now Prime and Bus Supplier in GEO: Viasat Selects Lightning-GEO for Anti-Jam Satellite

Rocket Lab was selected by Viasat to supply the satellite bus for Viasat’s U.S. Space Force anti-jam Protected Tactical SATCOM-Global (PTS-G) Swarm 1 spacecraft, using Rocket Lab’s Lightning-GEO platform. Viasat will integrate, operate, and lead the prime role; Rocket Lab builds the bus. The Swarm 1 delivery order totals about $437.7M across contractors; terms were not disclosed.

techtimes.com7 min
AUG 17
$LHXMed

L3Harris ousts CEO Kubasik over conduct violation

L3Harris Technologies said CEO Christopher Kubasik stepped down after a board investigation found misconduct and the company entered a separation agreement. The company did not disclose details, saying the conduct was unrelated to financial reporting or operations. Sam Mehta was named successor. Reuters reported no severance, but he can keep vested options. LHX shares fell.

foxbusiness.com3 min